197
Views
2
CrossRef citations to date
0
Altmetric
Research Articles

Design, synthesis and docking studies of novel 4-aminophenol-1,2,4-oxadiazole hybrids as apoptosis inducers against triple negative breast cancer cells targeting MAP kinase

, , , , , & show all
Pages 5841-5857 | Received 18 Apr 2023, Accepted 17 Jun 2023, Published online: 02 Aug 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Lohith Tumakuru Nagarajappa, Santhosh Chikkappaiahnayaka, Mofeli Benedict Leoma, Bienfait Kabuyaya Isamura, Karthik Venkatesh, Krishna Ravi Singh, Kishorkumar Sindogi, Sridhar Mandayam Anandalwar & Maralinganadoddi P. Sadashiva. Unraveling the crystal structure, stability and drug likeness of 1,3,4-oxadiazole derivatives against Myelofibrosis: a combined experimental and computational investigation. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-15.
Read now

Articles from other publishers (1)

Eid E. Salama, Mohamed F. Youssef, Ahmed Aboelmagd, Ahmed T. A. Boraei, Mohamed S. Nafie, Matti Haukka, Assem Barakat & Ahmed A. M. Sarhan. (2023) Discovery of Potent Indolyl-Hydrazones as Kinase Inhibitors for Breast Cancer: Synthesis, X-ray Single-Crystal Analysis, and In Vitro and In Vivo Anti-Cancer Activity Evaluation. Pharmaceuticals 16:12, pages 1724.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.